Material Transfer Agreement for transfer of biological material to non-profit organizations only Deutsches Krebsforschungszentrum, Stiftung des öffent

Similar documents
University of South Florida Pre-Approved Material Transfer Agreement Based upon the UBMTA

Part II. Plasmid Deposit and Distribution Terms and Conditions

MATERIAL TRANSFER AGREEMENT UNIVERSITI SAINS MALAYSIA ABC

MATERIAL TRANSFER AGREEMENT

CHDI FOUNDATION, INC. ("CHDI") MATERIAL TRANSFER AGREEMENT FOR CHDI MATERIALS

COLLABORATIVE RESEARCH AGREEMENT

SIMONS FOUNDATION AUTISM RESEARCH INITIATIVE (SFARI) SIMONS COLLECTION RESEARCHER DISTRIBUTION AGREEMENT (Revised October 2013)

Instruction Sheet for MCORE Software Agreement for Academic Centers (Non-profit)

NCIMB MATERIAL TRANSFER AGREEMENT

RESEARCH AGREEMENT BETWEEN THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK AND (SPONSOR)

Non-Proprietary User Agreement BETWEEN

CLI 社 HaCat(Human Skin keratinocyte:#300493) 使用目的確認書

NONEXCLUSIVE AGREEMENT

Material Transfer Agreement

U. S. DEPARTMENT OF ENERGY WORK FOR OTHERS AGREEMENT WITH A NON-FEDERAL SPONSOR. Strategic Partnership Project Agreement (SPP) No.

COMMERCIAL EVALUATION LICENSE AGREEMENT PURDUE RESEARCH FOUNDATION [ ] PRF Docket No.:

Sponsored Research Agreement

MASTER BIOLOGICAL MATERIAL DEPOSITORY AND DISTRIBUTION AGREEMENT

SERVICE CENTER AGREEMENT: COMMERCIAL USERS

[NAME OF ANALYTICAL RESEARCH FACILITY WHICH WILL BE IN CHARGE OF CARRYING OUT THE MEASUREMENTS] ARF

RESEARCH AGREEMENT. NOW, THEREFORE, in consideration of the terms and conditions set forth below, the parties agree as follows: Section 1 RESEARCH

Model Agreement SBIR/STTR Programs

Sponsored Clinical Research Agreement

Collaboration Agreement

UNIVERSITY OF MINNESOTA INDUSTRIAL PARTNERSHIP FOR RESEARCH IN INTERFACIAL AND MATERIALS ENGINEERING MEMBER PARTICIPATION AGREEMENT PURPOSE

This sample materials license is provided for illustrative purposes only. Any actual agreement may be subject to change.

STEVENSON-WYDLER (15 U.S.C. 3710a) COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (hereinafter CRADA ), No. YY-NNNC], between

OLIVE & OLIVE, P.A. INTELLECTUAL PROPERTY LAW

Your signature below will constitute acceptance of the provisions of this Agreement and of the attached General Terms and Conditions of Sale.

Agreement for the Provision of Digital Object Identifiers (DOI)

VISITING SCIENTIST AGREEMENT

End User License Agreement

SERVICE AGREEMENT. between. Ecole Polytechnique Fédérale de Lausanne (EPFL) CH Lausanne, Switzerland

Remote Deposit Capture Application End User License Agreement

SECTION 10 BOARD POLICIES AND PROCEDURES

Sodium Hydrogen Carbonate SIEF Agreement. This SIEF Agreement (hereinafter the Agreement ) is entered into by and between:

NOW, THEREFORE, Carnegie Mellon and the Member agree as follows:

CAMBIA DRAFT PMET BiOS 2.0 agreement

CERTIFICATE SUBSCRIBER AGREEMENT FOR DIGITAL CERTIFICATES

DATA SHARING AGREEMENT

DISTRIBUTOR AGREEMENT

- MODEL - Public Law , the Federal Technology Transfer Act of 1986, as amended.

Woodland Bank. Mobile Check Deposit Application End User License Agreement

Terms of Service Overview

1099 INDEPENDENT CONTRACTOR AUTHORIZATION PROCEDURES

I. Preamble. Patent Policy Page 1 of 13

Trial Period Terms and Conditions Product Supply Agreement

TERMS AND CONDITIONS OF SALE

Instructions for Completing Transgenic Mouse Ready To Sign Agreement

NON-STANDARD NAVY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN THE NAVAL RESEARCH LABORATORY (NRL) AND XYZ CORPORATION (XYZ)

FREE DOWNLOAD COMPONENTS/THIRD PARTY TERMS AND CONDITIONS PROGRAM: PowerBuilder Application Server Plug-in version 1.x

THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER TECHNOLOGY DEVELOPMENT PROGRAM MANUAL

AGREEMENT BETWEEN OWNERS OF PATENT RIGHTS

HUNGARY Patent Act Act XXXIII of 1995 as consolidated on March 01, 2015

IMPORTANT READ CAREFULLY BEFORE INSTALLING OR USING THIS PRODUCT

SUDAN Patents Act Act No. 58 of 1971 ENTRY INTO FORCE: October 15, 1971

AGREEMENT BETWEEN OWNERS OF PATENT RIGHTS

Please complete, sign and mail two copies of this agreement to: Licensee (Institution Name): Individual to Contact: Street Address:

TERMS AND CONDITIONS FOR THE SALE OF GOODS AND SERVICES

About The Beta Participant Agreement

Security Agreement Assignment of Hedging Account (the Agreement ) Version

LATVIA Patent Law adopted on 15 February 2007, with the changes of December 15, 2011

A Patents, Copyrights, Intellectual Property Policy

COLLABORATIVE RESEARCH AGREEMENT AND ALLOCATION OF RIGHTS IN INTELLECTUAL PROPERTY UNDER AN STTR RESEARCH PROJECT between. and

CADD Scores License Commercial

Supplier Portal Terms of Use

OZO LIVE EVALUATION SOFTWARE LICENSE AGREEMENT

UCSC GENOME BROWSER INTERNAL USE LICENSE

CLOUDVELOX, INC. Terms of Service

USER LICENSE AGREEMENT

SOFTWARE LICENCE. In this agreement the following expressions shall have the following meanings:

Contact Details. There are two options for payment, via bank transfer, Paypal or credit card. Choose one below:

INVENTION DISCLOSURE REPORT & ASSIGNMENT

BY-LAWS POST # CANTEEN/HOME ASSOCIATION, INCORPORATED VETERANS OF FOREIGN WARS OF THE UNITED STATES ARTICLE I NAME AND LOCATION

Calcium difluoride - SIEF Agreement. This SIEF Agreement (hereinafter the Agreement ) is entered into by and between:

CONTRIBUTION AGREEMENT VERSION 1.2

PURCHASE ORDER ATTACHMENT IP-006 ADDENDUM TO SOFTWARE LICENSES WITH RAYTHEON

H. Lee Moffitt Cancer Center and Research Institute, Inc. Patent and Copyright Agreement ( Agreement )

ABC-CLIO Database License Agreement

American Psychological Association (APA) PsycINFO /ClinPSYC License (Vendor Access)

SEI Biobased Participant Agreement

SERVICE AGREEMENT. In consideration of the mutual covenants set forth herein, the parties agree as follows:

BoardDocs End User Agreement Part I: Order Form

IxANVL Binary License Agreement

"Commercial Use" means distribution or otherwise making the Covered Code available to a third party.

VOLUNTARY REMEDIAL ACTION AGREEMENT

INTRA CONSORTIUM AGREEMENT for PPP PROJECTS

STANDARD TERMS AND CONDITIONS OF SALE

Topsfield Water Department Invitation to Bid Potassium Hydroxide June 1, 2007

TSANet DATABASE LICENSE AND MEMBER ACCEPTANCE AGREEMENT

Purchase Agreement (Goods)

Clinical Trial Research Agreement

License Agreement -SuSE Linux Openexchange Server (SLOX) 1. Definitions 1.1 "EULA" shall mean an End-User License Agreement.

Archipelago Trading Services, Inc.

DISTRIBUTION TERMS. In Relation To Structured Products

XYTEX TISSUE STORAGE, INC. SEMEN/TESTICULAR TISSUE STORAGE AGREEMENT FOR CLIENT DEPOSITOR

NOTICE: THIS IS A LEGALLY BINDING CONTRACT

PUBLICATIONS SUBSCRIPTION AND ACCESS AGREEMENT TERMS & CONDITIONS FOR SUBSCRIBERS TO THE ELECTRONIC PUBLICATIONS

ZEN PROTOCOL SOFTWARE LICENSE

JOINT MARKETING AND SALES REFERRAL AGREEMENT

Transcription:

Cell Lines Service Cell Lines Service Hildastrasse 21 69214 Eppelheim Germany Fon: +49 (0)6221-700799 Fax: +49 (0)6221-700717

Material Transfer Agreement for transfer of biological material to non-profit organizations only Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (German Cancer Research Center) located at Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany ("DKFZ") agrees to provide Organization: Address: Street: Zip code: City: Country: hereafter referred to as RECIPIENT with certain MATERIAL for use in the laboratory of Email: hereafter referred to as RECIPIENT SCIENTIST for the purpose of conducting scientific work under the following conditions: I. Definitions: 1. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES. 2. PROGENY: Unmodified descendant from the ORIGINAL MATERIAL, such as virus from virus, cell from cell, or organism from organism. 3. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. 4. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL.

5. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met. II. The ORIGINAL MATERIAL created by Profs. Dr. Petra Boukamp and Dr. Norbert Fusenig covered by this Agreement is: HaCaT cell lines Specified in Boukamp et al: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771 (1988). In any publications using this cell line this reference has to be cited. The MATERIAL listed above is considered proprietary to DKFZ. III. DKFZ and RECIPIENT agree that the MATERIAL: - is to be used solely for teaching and academic research purposes; - will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of DKFZ; IV. RECIPIENT shall not distribute or release the MATERIAL to any person other than laboratory personnel under RECIPIENT SCIENTIST s direct supervision and shall ensure that no one will be allowed to take or send this MATERIAL to any other location. DKFZ will control future distributions of the MATERIAL. At the written request of DKFZ, RECIPIENT will cease to use MATERIAL and will return (at DKFZ s option) all unused MATERIAL. V. DKFZ retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICATIONS. RECIPIENT retains ownership of: (a) MODIFICATIONS (except that DKFZ retains ownership rights to the MATERIAL included therein), and (b) those substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not

contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either (a) or (b) results from the collaborative efforts of DKFZ and RECIPIENT, joint ownership may be negotiated. VI. RECIPIENT shall have the right to distribute substances created by RECIPIENT through the use of the ORIGINAL MATERIAL, only if those substances are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS. Under a separate agreement at least as protective of DKFZ s rights as this Agreement, RECIPIENT may distribute MODIFICATIONS to non-profit organizations for research and teaching purposes only. RECIPIENT agrees that nothing in this Agreement shall be deemed to grant neither any rights under any DKFZ patents nor any rights to use the MATERIAL nor any products or processes involving the MATERIAL for profit-making or commercial purposes. The MATERIAL will not be used in research that is subject to consulting or licensing obligations to another corporation, company, or business entity. VII. RECIPIENT shall periodically inform DKFZ of research results related to the MATERIAL and will provide DKFZ with a copy of any manuscripts describing the results of such research at the time the manuscript is submitted for publication. RECIPIENT shall mention DKFZ by name and the responsible researcher citing the following original publication: Boukamp et al: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771 (1988) VIII. THE MATERIAL IS EXPERIMENTAL IN NATURE AND IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. DKFZ MAKES NO REPRESENTATION OR WARRANTY THAT THE MANUFACTURE, SALE, TRANSFER OR USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHT OF OTHERS. IX. RECIPIENT shall notify DKFZ promptly in writing of any invention, improvement, modification, discovery, or development (each, an "Invention") of MATERIAL or associated know how and data conceived or reduced to practice in the course of the RECIPIENT s research with MATERIAL or associated know how and data. In the patent applications DKFZ resp. DKFZ employees shall be mentioned as coinventors according to their contribution to the invention, if appropriate under statutory provisions.

X. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER. XI. Should any provision of this agreement be invalid or unenforceable or should the contract contain an omission, the remaining provisions shall be valid. In the place of an invalid provision, a valid provision is presumed to be agreed upon by the parties, which comes economically closest to the invalid provision. The same shall apply in the case of an omission. This wording contains the entire agreement between the parties; any changes of the agreement have to be made in writing. For RECIPIENT: RECIPIENT SCIENTIST Signature:.. Authorized Official of RECIPIENT (Person authorized to bind RECIPIENT legally by his/her signature) Position: Signature:..

Material Transfer Agreement for transfer of biological material to non-profit organizations only Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts (German Cancer Research Center) located at Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany ("DKFZ") agrees to provide Organization: Address: Street: Zip code: City: Country: hereafter referred to as RECIPIENT with certain MATERIAL for use in the laboratory of Email: hereafter referred to as RECIPIENT SCIENTIST for the purpose of conducting scientific work under the following conditions: I. Definitions: 1. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES. 2. PROGENY: Unmodified descendant from the ORIGINAL MATERIAL, such as virus from virus, cell from cell, or organism from organism. 3. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. 4. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL.

5. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met. II. The ORIGINAL MATERIAL created by Profs. Dr. Petra Boukamp and Dr. Norbert Fusenig covered by this Agreement is: HaCaT cell lines Specified in Boukamp et al: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771 (1988). In any publications using this cell line this reference has to be cited. The MATERIAL listed above is considered proprietary to DKFZ. III. DKFZ and RECIPIENT agree that the MATERIAL: - is to be used solely for teaching and academic research purposes; - will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of DKFZ; IV. RECIPIENT shall not distribute or release the MATERIAL to any person other than laboratory personnel under RECIPIENT SCIENTIST s direct supervision and shall ensure that no one will be allowed to take or send this MATERIAL to any other location. DKFZ will control future distributions of the MATERIAL. At the written request of DKFZ, RECIPIENT will cease to use MATERIAL and will return (at DKFZ s option) all unused MATERIAL. V. DKFZ retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICATIONS. RECIPIENT retains ownership of: (a) MODIFICATIONS (except that DKFZ retains ownership rights to the MATERIAL included therein), and (b) those substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not

contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either (a) or (b) results from the collaborative efforts of DKFZ and RECIPIENT, joint ownership may be negotiated. VI. RECIPIENT shall have the right to distribute substances created by RECIPIENT through the use of the ORIGINAL MATERIAL, only if those substances are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS. Under a separate agreement at least as protective of DKFZ s rights as this Agreement, RECIPIENT may distribute MODIFICATIONS to non-profit organizations for research and teaching purposes only. RECIPIENT agrees that nothing in this Agreement shall be deemed to grant neither any rights under any DKFZ patents nor any rights to use the MATERIAL nor any products or processes involving the MATERIAL for profit-making or commercial purposes. The MATERIAL will not be used in research that is subject to consulting or licensing obligations to another corporation, company, or business entity. VII. RECIPIENT shall periodically inform DKFZ of research results related to the MATERIAL and will provide DKFZ with a copy of any manuscripts describing the results of such research at the time the manuscript is submitted for publication. RECIPIENT shall mention DKFZ by name and the responsible researcher citing the following original publication: Boukamp et al: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771 (1988) VIII. THE MATERIAL IS EXPERIMENTAL IN NATURE AND IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. DKFZ MAKES NO REPRESENTATION OR WARRANTY THAT THE MANUFACTURE, SALE, TRANSFER OR USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHT OF OTHERS. IX. RECIPIENT shall notify DKFZ promptly in writing of any invention, improvement, modification, discovery, or development (each, an "Invention") of MATERIAL or associated know how and data conceived or reduced to practice in the course of the RECIPIENT s research with MATERIAL or associated know how and data. In the patent applications DKFZ resp. DKFZ employees shall be mentioned as coinventors according to their contribution to the invention, if appropriate under statutory provisions.

X. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER. XI. Should any provision of this agreement be invalid or unenforceable or should the contract contain an omission, the remaining provisions shall be valid. In the place of an invalid provision, a valid provision is presumed to be agreed upon by the parties, which comes economically closest to the invalid provision. The same shall apply in the case of an omission. This wording contains the entire agreement between the parties; any changes of the agreement have to be made in writing. For RECIPIENT: RECIPIENT SCIENTIST Signature:.. Authorized Official of RECIPIENT (Person authorized to bind RECIPIENT legally by his/her signature) Position: Signature:..